Absence of Neisseria meningitidis serogroup C-specific antibodies during the first year of life in the Netherlands: an age group at risk?
In The Netherlands, a single meningococcal serogroup C conjugate (MenCC) vaccination is administered to children at the age of 14 months. Here, we report the levels of MenC polysaccharide-specific antibodies in children at birth and at 3, 11, and 12 months of age and the presence of functional antibodies at 11 months of age, before infants receive their MenCC immunization. We observed a rapid decline in polysaccharide-specific antibodies after birth and no induction of naturally elicited polysaccharide-specific antibodies. Furthermore, at 11 months of age, no bactericidal antibodies are observed. These data indicate that these infants may be at risk in the period prior to MenCC immunization, if Neisseria meningitidis serogroup C starts to (re)circulate.
de Voer
Richarda M
RM
Laboratory for Infectious Diseases and Screening, National Institute of Public Health and the Environment, Bilthoven, The Netherlands. Richarda.de.Voer@rivm.nl
van der Klis
Fiona R M
FR
Niers
Laetitia E M
LE
Rijkers
Ger T
GT
Berbers
Guy A M
GA
D000367:Age Factors; D000907:Antibodies, Bacterial / Q000097:blood*; D000918:Antibody Specificity; D001770:Blood Bactericidal Activity; D005260:Female; D005312:Fetal Blood / Q000276:immunology; D006801:Humans; D007115:Immunization Schedule; D007074:Immunoglobulin G / Q000097:blood; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008585:Meningitis, Meningococcal / Q000276:immunology / Q000517:prevention & control; D022401:Meningococcal Vaccines / Q000008:administration & dosage; D038542:Neisseria meningitidis, Serogroup C / Q000276:immunology* / Q000472:pathogenicity; D009426:Netherlands; D011135:Polysaccharides, Bacterial / Q000008:administration & dosage; D012307:Risk Factors
D000907:Antibodies, Bacterial; D007074:Immunoglobulin G; D022401:Meningococcal Vaccines; D011135:Polysaccharides, Bacterial
Euro Surveill. 2006 Mar 02;11(3):E060302.4
16804223
Clin Vaccine Immunol. 2009 Mar;16(3):433-6
19129470
Clin Infect Dis. 2009 Jul 1;49(1):58-64
19480581
Vaccine. 2007 Oct 10;25(41):7233-7
17707957
Pediatr Infect Dis J. 2005 Feb;24(2):128-31
15702040
Vaccine. 2003 Mar 7;21(11-12):1094-8
12559785
Clin Vaccine Immunol. 2008 Nov;15(11):1694-8
18827191
Vaccine. 2009 May 26;27(25-26):3435-8
19200821
Pediatr Infect Dis J. 2006 Jan;25(1):79-80
16395110
Arch Dis Child Fetal Neonatal Ed. 1996 Jan;74(1):F43-6
8653435
Vaccine. 2006 Apr 24;24(17):3500-4
16517032
Vaccine. 2001 Oct 15;20 Suppl 1:S58-67
11587814
Clin Vaccine Immunol. 2009 Feb;16(2):194-9
19091990
Euro Surveill. 2006 Sep 07;11(9):E060907.4
17075143
J Infect Dis. 2008 Mar 1;197(5):737-43
18271745
Clin Diagn Lab Immunol. 1997 Mar;4(2):156-67
9067649
Pediatr Infect Dis J. 2002 Aug;21(8):747-53
12192163